China Greenlights Home-Injectable Alzheimer's Drug Leqembi, Easing Patient Burden
Context mode is active. Hover over any highlighted term to see its definition. Click a nested term to go deeper.
China's National Medical Products Administration (NMPA) has just approved a groundbreaking subcutaneous, self-administered version of Eisai and Biogen's Alzheimer's drug, Leqembi, on September 2, 2026. This game-changing move allows patients with early Alzheimer's disease in China to receive their weekly treatment at home via an autoinjector, a significant leap from the bi-weekly hospital-based intravenous infusions that were previously the only option for this anti-amyloid therapy. The approval marks China as only the second country globally, after the United States in July 2026, to clear this more convenient formulation for initiation treatment, promising to transform patient access and ease the immense care burden. The shift to a home-injectable formulation directly addresses major hurdles in Alzheimer's treatment, particularly for China's estimated 17 million early AD patients, a number projected to grow. Previously, patients required hospital visits for roughly hour-long IV infusions, which placed a heavy logistical and emotional toll on individuals and their caregivers. The new subcutaneous option, administered in two quick 15-second injections once a week, maintains similar clinical benefits and safety profiles as the IV version but drastically reduces clinic time and healthcare resource strain, offering unprecedented flexibility for patients. With the launch planned during Eisai's fiscal year 2026 (ending March 31, 2027), this approval sets the stage for a broader global rollout of at-home Alzheimer's treatment, with applications currently under review in other key markets like Japan. The increased accessibility is expected to encourage earlier and more consistent treatment initiation, which is crucial for maximizing Leqembi's efficacy in slowing cognitive decline. Industry watchers will now be keen to see how this simplified delivery method accelerates adoption and reshapes the future of neurodegenerative disease management worldwide.